Ypsomed : Presentation of Half-Year Results 2022/23 (2.8 MiB)
November 16, 2022 at 08:39 am
Share
Ypsomed Half-Year Results 2022/23
Strong rise in profitability
Webcast, 16 November 2022
PUBLIC
Important information
The information contained in this document has not been verified by an independent source. It should be taken with caution and no assurance or guarantee is given (either explicit or implied) with regard to the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG nor advisors or affiliates of Ypsomed Holding AG shall be liable in any way for losses occurred in conjunction with the use of this document, its contents or any other connection with this document. This document is neither an offer (or part of an offer) for the sale, nor a solicitation for the purchase of shares, and neither the document nor parts thereof form the basis of any contract or otherwise obligation. This document contains future-oriented statements which include uncertainties and risks. Such statements are indicated by such words as "could", "planned", "expected", "believed" and similar expressions or their context. These statements are made based on current knowledge and current assumptions. Due to a variety of different factors, the actual future results, developments or events may deviate considerably from those mentioned here. There is no obligation whatsoever to update future-oriented statements.
2 | Ypsomed Holding AG | Half-Year Results 2022/23
PUBLIC
Making selfcare simpler and easier
Improved therapy outcomes for chronic conditions
3 | Ypsomed Holding AG | Half-Year Results 2022/23
PUBLIC
Making selfcare simpler and easier
Improved therapy outcomes for chronic conditions
4 | Ypsomed Holding AG | Half-Year Results 2022/23
PUBLIC
Solutions for healthcare's biggest challenge
Ypsomed's underlying growth fundamentals are unchanged
Selfcare
Improving quality of life, therapy adherence and enabling affordable healthcare systems
Biologics
Most new-generation drugs with complex active pharmaceutical ingredients have to be injected
Biosimilars
Expanding affordable, global access to medical care
Digitization
Enabling innovative, digital therapy management for optimal therapy outcomes and evidence-based care
5 | Ypsomed Holding AG | Half-Year Results 2022/23
PUBLIC
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Ypsomed Holding AG published this content on 16 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2022 08:38:08 UTC.
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
YPSOMED HOLDING AG 
